Helius Medical Technologies (HSDT) to Release Quarterly Earnings on Monday
Helius Medical Technologies (HSDT) to Release Quarterly Earnings on Monday
Helius Medical Technologies (NASDAQ:HSDT – Get Rating) will be announcing its Q2 earnings results after the market closes on Monday, August 15th. Analysts expect the company to announce earnings of ($1.12) per share for the quarter.
赫利烏斯醫療技術公司(納斯達克代碼：HSDT-GET Rating)將在8月15日星期一收盤後公佈第二季度收益結果。分析師預計，該公司將公佈本季度每股收益(1.12美元)。
Helius Medical Technologies (NASDAQ:HSDT – Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($1.15) EPS for the quarter. Helius Medical Technologies had a negative net margin of 3,043.95% and a negative return on equity of 240.53%. The business had revenue of $0.19 million during the quarter. During the same quarter in the previous year, the company posted ($1.65) earnings per share. On average, analysts expect Helius Medical Technologies to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
和力士醫療技術公司(納斯達克代碼：HSDT-GET Rating)最近一次發佈財報是在5月12日星期四。該公司公佈本季度每股收益(1.15美元)。赫利烏斯醫療技術公司的淨利潤率為負3,043.95%，淨資產回報率為負240.53%。該業務在本季度的收入為19萬美元。去年同期，該公司公佈的每股收益為1.65美元。分析師平均預計，Helius Medical Technologies本財年每股收益為-4美元，下一財年為-2美元。
Helius Medical Technologies Price Performance
Helius醫療技術性價比
Helius Medical Technologies stock opened at $0.55 on Friday. Helius Medical Technologies has a 12-month low of $0.45 and a 12-month high of $15.68. The company has a market capitalization of $2.09 million, a price-to-earnings ratio of -0.08 and a beta of 0.72. The firm's fifty day moving average price is $1.24 and its 200 day moving average price is $2.45.
Helius醫療技術公司的股票週五開盤報0.55美元。Helius Medical Technologies的12個月低點為0.45美元，12個月高位為15.68美元。該公司市值為209萬美元，市盈率為-0.08倍，貝塔係數為0.72。該公司的50日移動均線價格為1.24美元，200日移動均線價格為2.45美元。
About Helius Medical Technologies
關於Helius醫療技術公司
Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.
Helius醫療技術公司是一家神經技術公司，專注於開發、許可和獲取非侵入性技術，用於治療神經疾病或創傷引起的症狀。其產品便攜式神經調節刺激器(PONS)是一種非手術醫療設備，旨在用於短期治療因多發性硬化症症狀而導致的步態缺陷和因輕至中度創傷性腦損傷而導致的平衡障礙，以及與有監督的治療鍛鍊一起使用。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Helius Medical Technologies (HSDT)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免費獲取StockNews.com關於Helius醫療技術(HSDT)的研究報告
- 值得關注的兩場重要的零售股大戰
- MarketBeat：回顧中的一週2012-8-8
- 什麼是WallStreetBets，他們的目標是什麼股票？
- 機構和分析師推動Jack in the Box走高
- 你能猜到哪個電動車股票打敗了特斯拉嗎？
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《赫利烏斯醫療技術日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Helius醫療技術公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。